Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 176,141

Document Document Title
WO/2018/226992A1
This invention relates to the field of tau aggregation inhibitors. More specifically, the invention relates to anti-amyloid therapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating aggre...  
WO/2018/224869A1
The present invention relates to a composition comprising: astaxanthin, piperine, boswellic acids, coenzyme Q10, curcuminoids, lutein, zeaxanthin, saffron, copper and, optionally, resveratrol, bromelain, zinc, salicin and further antioxi...  
WO/2018/223909A1
Provided is a chimeric molecule consisting of a small molecule compound unit of a target protein, an E3 ubiquitin ligase binding unit and a linkage unit. The chimeric molecule can bind to a BRD protein, enable the BRD protein to be more ...  
WO/2018/226776A1
Provided are compositions and methods for autophagosome completion assays useful for detecting and monitoring phagophore closure and autophagosome maturation, and for screening for compounds effective for the treatment of diseases or dis...  
WO/2018/226339A1
The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases in pediatric subjects, and related methods.  
WO/2018/226735A1
A method inhibiting and/or reducing β-amyloid accumulation and/or Tau aggregation in a subject in need thereof includesadministering to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and func...  
WO/2018/227187A1
Cyclic peptide pro-gelator compositions, and methods of therapeutic use, which assemble into macromolecular hydrogel when administered through cleavage by endogenous enzymes upregulated at a site of tissue injury, such as a myocardial in...  
WO/2018/227176A1
In spite of significant efforts to identify β-cell-specific markers for β-cell imaging and purification, progress has been limited. Herein is disclosed a novel biomarker of human pancreatic β-cells, CD39L3 (also known as ectonucleosid...  
WO/2018/226853A1
Provided are compositions, methods, and kits for improving CRISPR-based editing of DNA targets by a CRISPR-associated (Cas) enzyme. The improvement is made by combining the Cas enzyme and a CRISPR targeting RNA a heterologous DNA repair ...  
WO/2018/224516A1
A method for determining the presence or absence of a piscine myocarditis virus infection, in a biological sample obtained from a cleaner fish using an isolated or synthetic nucleic acid encoding a piscine myocarditis virus polypeptide, ...  
WO/2018/225662A1
Natural immunity is induced in a subject animal by administering to the subject animal a fused protein comprising at least two toxin B subunits selected from among the B subunit of Shiga toxin 2e (Stx2eB), the B subunit of a heat-labile ...  
WO/2018/225790A1
The present application discloses a crystal of an oxidized glutathione dication salt and a production method for the crystal.  
WO/2018/227030A1
Disclosed herein is a system and methods for determining the alleles, neoantigens, and vaccine composition as determined on the basis of an individual's tumor mutations. Also disclosed are systems and methods for obtaining high quality s...  
WO/2018/226958A1
Described herein are methods for producing and utilizing T cells comprising chimeric antigen receptors (CAR) comprising an extracellular domain that binds CD79b, or CD79b and CD 19. Further, this invention is related to methods of treati...  
WO/2018/226975A1
Provided herein are cationic liquid crystalline nanoparticles (CLCNs). Further provided herein are methods of delivering RNAi using the CLCNs for the treatment of diseases.  
WO/2018/224053A1
The present invention belongs to the field of pharmaceutical preparations and relates to designing a series of lipophilic derivatives by using the wild-type membrane-penetrating peptide penetratin. These penetratin derivatives have a str...  
WO/2018/224477A1
The present invention relates to a phycocyanin composition for use in inhibiting bone resorption in humans or animals.  
WO/2018/225851A1
A method for producing a peptide containing an N-substituted amino acid or an N-substituted amino acid analogue according to the present invention includes the steps of: preparing an Fmoc-protected amino acid, an Fmoc-protected amino aci...  
WO/2018/223764A1
Disclosed are a human sDR5-Fc recombinant fusion protein and the use of same in the preparation of a drug for treating reproductive system inflammation. In particular, a fusion protein of the soluble fragment of the human DR5 and the Fc ...  
WO/2018/226861A1
Compositions and methods for treating enzyme-deficiency diseases are disclosed. Multidomain therapeutic proteins containing an internalization effector binding domain and a lysosomal replacement enzyme activity are disclosed. The multido...  
WO/2018/225440A1
The purpose of the present invention is to provide a therapeutic agent for dilated cardiomyopathy disease which produces excellent effects in the treatment of dilated cardiomyopathy (DCM) and provides a given benefit to a large number of...  
WO/2018/224043A1
Provided are applications of an upstream Open Reading Frame (uORF) of a Phosphatase and Tensin homolog (PTEN) gene and a polypeptide coded by the same. A a potential ORF of 96 bases (31aa-uORF) existing in the 5' UTR of the PTEN can code...  
WO/2018/224843A1
The invention provides a combination comprising a compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable derivatives or prodrugs thereof and a polymyxin selected from polymyxin E and polymyxin B or a pharmac...  
WO/2018/224689A2
The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.  
WO/2018/225041A1
Provided are methods for treating high cardiovascular risk patients with hypercholesterolemia and type 1 or type 2 diabetes mellitus receiving insulin therapy. These methods generally comprise administering to a patient a pharmaceutical ...  
WO/2018/225623A1
Provided are a lactase bulk powder and a lactase preparation both having improved storage stability. The stability of a lactase bulk powder is improved by regulating the acceptable amount of glucose and/or galactose, which are inevitably...  
WO/2018/224665A1
The present invention provides valuable peptidomimetics for therapeutic and diagnostic purposes as well as compositions, methods, uses and kits based on these peptidomimetics. In particular, the peptidomimetics of the present invention a...  
WO/2018/226750A1
This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides...  
WO/2018/223763A1
Provided are a pharmaceutical composition and the use of the same in the preparation of a drug for treating liver injury. The pharmaceutical composition comprises a tumour necrosis factor antagonist and a tumour necrosis factor-related a...  
WO/2018/224559A1
The invention relates to a microneedle system (MNS) for intradermal application in a controlled release of glucagon-like peptide analogues.  
WO/2018/226058A2
The present invention relates to a pharmaceutical composition for preventing or treating a neovascular disease, comprising collagen and a 34-mer pigment epithelium derived factor (PEDF) peptide as active ingredients. More particularly, t...  
WO/2018/224550A1
The application relates to a fusion protein comprising an antibody molecule, or antigen-binding fragment thereof, and a member of the vascular endothelial growth factor family, such as VEGF-C or VEGF- D. The antibody molecule preferably ...  
WO/2018/223227A1
There are provided compositions and methods for prevention or treatment of atherosclerosis and related disorders. More specifically, there are provided desmocollin 1 inhibitor compounds and pharmaceutical compositions thereof for use in ...  
WO/2018/226119A1
The present invention relates to the fields of medicine, hygiene, cosmetology and veterinary and could be used for preventing bacterial biofilm formation and disrupting biofilms formed by pathogenic and opportunistic bacteria of various ...  
WO/2018/227053A1
The disclosure is directed to compounds and methods for preparing purified macrocyclic peptide using "catch-release" methods. These methods comprise reacting a free amino group of a resin-bound linear peptide with an azide- or alkyne-fun...  
WO/2018/225961A1
The present invention relates to a novel peptide and a pharmaceutical composition for treatment of eye diseases comprising the novel peptide as an active ingredient. When the novel peptide of the present invention is applied to an eye, t...  
WO/2018/227178A1
The present invention provides carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections, including drug resistant or multiple-drug resistant bacterial infections, and methods for treating such ...  
WO/2018/223114A1
Disclosed herein are glucose-sensitive drug delivery systems including polymeric shell encapsulating an active agent. Upon exposure to a sufficient concentration of glucose, the shell is ruptured, releasing the active agent for absorption.  
WO/2018/221480A1
[Problem]To provide a novel technique, which is more effective in the treatment of portal vein thrombosis. [Solution] This portal vein thrombosis therapeutic agent contains an antithrombin III as an active ingredient, is administered to ...  
WO/2018/222987A1
Protein-binding moieties, such as antibody mimetics that bind to proteins such as FcRn, albumin, or IgG, and targeted constructs comprising the protein-binding moieties have been designed which can provide improved temporospatial deliver...  
WO/2018/222186A1
An assay and a method for detecting how much active PCSK9 is available in a sample to bind to the LDL receptor. Active PCSK9 is PCSK9 that is not bound to a LDL receptor and is available to bind to a LDL receptor. An aspect of the assay ...  
WO/2018/222962A1
Described herein are compositions and methods for treating a lung disorder associated with dysregulated VEGF signaling. The PR1P peptide (DRVQRQTTTVVA, SEQ ID NO: 1) and variants thereof are able to enhance VEGF signaling in the lungs an...  
WO/2018/219959A1
The present invention relates to a method for predicting the probability of having or developing a non-fusion, wherein said method comprises determining the frequency of a subpopulation of CD8+ T cells selected from CD8+CD57+, CD8+CD28- ...  
WO/2018/219278A1
This invention provides a method for preparing CAR-T cells, comprising: providing cells comprising a chimeric antigen receptor; and culturing the cells in the presence of an agent that an extracellular domain of the CAR binds to obtain C...  
WO/2018/220916A1
Provided is a composition that exhibits the following: an excellent permeability into the skin by amino acids, derivatives thereof, and active ingredients; no timewise change in odor and performance; low irritancy; and an excellent tacti...  
WO/2018/222670A1
Provided herein are methods and compositions for treating inflammatory diseases by administering to the subject an effective dose of an anti-alpha5 agent. Specifically, the methods are provided for the treatment of inflammatory diseases,...  
WO/2018/222611A1
Provided herein are compositions and methods for generating visible light photopolymerized hydrogels to support cell viability, expansion, and encapsulation. The present disclosure provides a composition, comprising a visible light harve...  
WO/2018/222792A1
The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to optimized polynucleotide sequences ...  
WO/2018/220232A1
The present invention is directed to a pharmaceutical combination product comprising botulinum toxin and atleast one proerectile agent for simultaneous, sequential or separate use in the treatment of erectile dysfunction.  
WO/2018/218710A1
Provided are chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting ex...  

Matches 1 - 50 out of 176,141